v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue:        
Contract research revenue $ 89,812 $ 89,812
Costs and expenses:        
Research and development 3,410,237 2,828,776 7,497,120 5,143,477
General and administrative 2,356,310 1,781,717 4,615,941 3,570,131
Total costs and expenses 5,766,547 4,610,493 12,113,061 8,713,608
Loss from operations (5,766,547) (4,520,681) (12,113,061) (8,623,796)
Sale of New Jersey net operating loss 1,007,082 1,073,289 1,007,082
Other income, net 156,000 168,872 383,327 221,279
Net loss (5,610,547) (3,344,727) (10,656,445) (7,395,435)
Preferred stock series A accumulated dividends (146,786) (293,572)
Preferred stock series B accumulated dividends (177,092) (115,750) (347,792) (234,000)
Net loss attributable to common shareholders $ (5,787,639) $ (3,607,263) $ (11,004,237) $ (7,923,007)
Net loss available for common shareholders per share - basic and diluted $ (0.03) $ (0.03) $ (0.06) $ (0.06)
Weighted average common shares outstanding - basic and diluted 197,601,500 143,104,941 194,636,326 130,306,907
Other comprehensive (loss)/income, net of tax        
Net unrealized (loss)/gain on securities available-for-sale $ (41,954) $ 481,303
Reclassifications to net loss (2,708) (2,719)
Other comprehensive (loss)/income, net of tax (44,662) 478,584
Comprehensive loss attributable to shareholders $ (5,655,209) $ (3,344,727) $ (10,177,861) $ (7,395,435)

Source